ClinicalTrials.gg
Not yet recruitingNCT07422311Updated Feb 25, 2026

To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease

A Phase 2/3 interventional study of Dronabinol Oral Solution and Placebo Control in Agitation in Dementia, sponsored by Benuvia Therapeutics Inc.. Not yet recruiting at 1 site in Australia. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Benuvia Therapeutics Inc. · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

This study tests a medication called dronabinol in people with Alzheimer's disease. First, participants go through up to 4 weeks of screening. Then, over 2 weeks, the dose of the study drug is slowly increased. For the next 10 weeks, participants stay on either dronabinol or a placebo.

After finishing this part of the study, participants can join a 6-month extension where everyone receives dronabinol. Those already on the drug stay on their same dose, while those who were on placebo gradually increase their dose over 2 weeks.

All participants take dronabinol for the rest of the extension, then complete a final safety check 4 weeks after stopping the medication. Usual medical treatments are continued throughout the study.

Read the detailed description

This is a randomised, double-blind, placebo-controlled study conducted in patients with a diagnosis of AD. The study consists of a screening period of up to 28 days (4 weeks), a 2-week titration period, during which the dose of dronabinol is gradually increased to the target maintenance dose. This is followed by a 10-week maintenance period (Weeks 3 through 12), where the target dose is maintained.

Following the 10-week maintenance period, eligible participants who complete the double-blind treatment period may enter a 6-month (24-week) open-label extension (OLE) to assess long-term safety and tolerability of dronabinol oral solution. Participants originally randomised to active treatment will continue receiving their established dose (2.5 mg, 5 mg, or 9.0 mg/day) without interruption. Participants originally randomised to placebo will undergo a 2-week titration period (Weeks 13 to 14) following the same dose escalation schedule as the main study to reach their target maintenance dose. All participants will receive open label dronabinol during the OLE period (Weeks 15 to 38). A final safety follow-up assessment will be conducted at Week 42 (4 weeks after the last dose of study medication). Standard of care medication will be maintained throughout this study for all participants as per the inclusion/exclusion criteria.

Titration/Transition Schedule:

Week 1/35: The starting dose will be 2.5 mg dronabinol once a day (QD) Week 2/14: Dronabinol dose will be increased to 2.5 mg twice a day (BID) for a total daily dose of 5 mg/day. Optional up-titration (Week 3/15 onwards, if tolerated) to 4.5 mg BID (total daily dose 9.0 mg/day).

Note: maximum dose in this study is 4.5 mg BID.

Dose escalation should occur only when a participant demonstrates BOTH:

Optimal safety profile:

Participant has completed ≥7 consecutive days at 5 mg/day without any clinically significant AE or group of AEs that singularly or in aggregate suggests to the Investigator or Sponsor that the study intervention is poorly tolerated and further treatment per protocol may not be safe (i.e., Grade 3 or above clinically significant AE deemed related to study intervention occurring in at least 2 study participants).

Suboptimal efficacy profile: Minimal or inadequate therapeutic response, defined by specific quantitative thresholds on validated agitation scales

02

Conditions studied

  • Agitation in Dementia
03

In context

Lead sponsor

This is the only study on the registry with Benuvia Therapeutics Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Participant or legal representative is willing and capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form and is willing and able to return for all study visits and comply with all protocol requirements and procedures.
  • 2. Adult males and females, 50 to 90 years of age (inclusive) at screening.
  • 3. Participants must have a diagnosis of dementia due to AD according to the , Fifth Edition (DSM-5) and a diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).
  • 4. Presence of Agit-AD as defined by the provisional criteria from the International Psychogeriatric Association (IPA). The definition requires the presence of cognitive impairment, evidence of emotional distress, one of three observable types of behaviour (excessive motor activity, verbal aggression, physical aggression), requires that the behaviour cause excess disability, and notes that the behaviours cannot be solely attributable to another disorder such as psychiatric illness, medical illness, or effects of substance use.
  • 5. severity of agitation defined by NPI-C Agitation or NPI-C Aggression >4.
  • 6. Mini Mental Status Examination () score of 8-20 (inclusive).
  • 7. Cohen-Mansfield Agitation Inventory (CMAI) total score ≥60 at both Screening and Baseline visits, with at least one item in the aggressive behaviour domain (Factor 1) scored >3 (occurring ≥ once or twice per week). Alternatively, meet Factor 1 positivity criterion: one or more aggressive behaviours occurring several times per week, OR two or more occurring once or twice per week, OR three or more occurring less than once per week.
  • 8. If a participant is receiving AD-specific treatment, they must have been on a stable dose for >3 months prior to first dose of study drug.
  • 9. Participant must have at least 1 study partner (e.g., spouse or caregiver in close contact) to support participant in all scheduled study visits and procedures.
  • 10. Participants who do not live in assisted living facilities are eligible to participate and must be capable of returning for study visits.
  • 11. Adequate vision and hearing (with corrective devices if needed) to complete study assessments, as judged by the investigator. Participants must be able to:

    1. Read and understand consent documents and questionnaires
    2. Hear and respond to verbal instructions for cognitive testing
    3. Participate in clinical interviews
  • 12. Has adequate hematologic and organ function, as indicated by the following laboratory values, prior to Cycle 1 Day 1:

    1. ≥1500/mm3; or 1.5 x 109/L
    2. count ≥100,000/mm3; or 1.0 x 109/L
    3. ≥8 g/dL
    4. Adequate renal function characterized by estimated ≥50 mL/min Chronic Kidney Disease Epidemiology Collaboration equation (CKDEPI).
    5. Total ≤1.5 x (≤3 x ULN for participants with Gilbert's syndrome).
    6. and ALT ≤3 x ULN.
  • 13. Female patients:

    a. Must be of non- i.e., surgical menopause (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone [FSH] level consistent with postmenopausal status, per local laboratory guidelines), or b. If of child-bearing potential, must: i. Have a negative pregnancy test at the screening visit and on admission to the study site on Day-1.

ii. Agree not to attempt to become pregnant or donate ova from signing the ICF until at least 30 days after the last dose of study drug.

iii. Agree to use adequate (defined as use of a condom by the male partner combined with use of a highly effective method of contraception [Section 10.4.3]) from one month prior to screening until at least 30 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.

  • 14. Male patients:

    1. Must agree not to donate sperm from signing the ICF until at least 90 days after the last dose of study drug.
    2. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception [Section 10.4.3]) from signing the ICF until at least 90 days after the last dose of study drug.
    3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, must agree to use a condom from signing the ICF until at least 5 half-lives of IP after the last dose of study drug.
  • 15. Have suitable venous access for blood sampling.
  • 16. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

  • 1. Known to the study drug or any of the study drug ingredients.
  • 2. History of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer's ability to participate in the study.
  • 3. History or presence of , unstable (not well controlled on medications) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, within the past 3 months determined by the PI (or delegate) to be clinically relevant.
  • 4. History of recurrent falls (≥2 falls within 6 months prior to Screening) resulting in injury or associated with acute illness, loss of consciousness, or abnormal vital signs, history of fall with fracture within 12 months of Screening.
  • 5. History of surgery or hospitalisation within 3 months prior to screening, or surgery planned during the study.
  • 6. Any history of malignant disease in the last 5 years (excludes surgically resected skin squamous cell or basal cell carcinoma).
  • 7. History of clinically significant CNS event and/or diagnosis in the past 5 years, including but not limited to epilepsy, significant CNS trauma, CNS surgery, neurosyphilis, meningitis, encephalitis or meningoencephalitis.
  • 8. Baseline delirium as determined by Confusion Assessment Method (CAM) and (DSM) - criteria.
  • 9. Commencement of medications that affect the CNS within \<4 weeks prior to first dose of study drug, including but not limited to cannabinoid, benzodiazepines, anti-depressant, and antipsychotic medications.
  • 10. History of major psychiatric disorder(s) in the past 5 years, including but not limited to psychosis and bipolar disorder. Mild psychiatric disorder(s) that is well controlled and stable on medication therapy for >1 year that is not prohibited on this study may be allowed on a case-by-case basis in discussion with study sponsor, if deemed unlikely to put participant at a higher risk of treatment-related toxicity and/or interfere with the integrity of study outcome.
  • 11. A history of or positive test results for (HIV), surface antigen (HBsAg) or virus (HCV) antibodies at the screening visit. A negative HCV RNA result is acceptable for enrolment.
  • 12. Medications with significant drug-drug interaction potential:

    1. Strong or CYP2C9 inhibitors (e.g., ketoconazole, ritonavir, fluconazole, amiodarone) within 2 weeks of Screening or anticipated need during study
    2. disulfiram/metronidazole (risk due to alcohol content)
  • 13. Positive drugs of abuse test (for a list of drugs tested refer to Section 11.1.8), cotinine test, or alcohol breath test results at screening and prior to dosing on Day 1.
  • 14. Regular consumption of more than 10 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], or 30 mL spirit [40% Alc/Vol]).
  • 15. Patient smokes more than 5 cigarettes or equivalent nicotine-containing products per week, and/or the volunteer is unwilling to abstain from smoking or the use of nicotine-containing products. Note: 1 average cigar = approx. 5 average cigarettes; 1 average pipe session = approx. 5 average cigarettes; 1 average nicotine liquid vape session = 1 average e-cigarette = 1 average cigarette.
  • 16. Females who are breastfeeding or planning to breastfeed from pre-dose to 90 days post last dose
  • 17. Is not able to reliably and regularly swallow liquid oral medications on a daily basis.
  • 18. Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medication within 10 days prior to first dose of study drug.
  • 19. Use of within 30 days prior to screening. Use of (non-live) booster vaccines is acceptable for enrolment.
  • 20. Participation in another clinical study of an drug or investigational device within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to screening.
  • 21. Any other condition or prior therapy that in the opinion of the PI (or delegate) would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
  • 22. History or current presence of unexplained recurrent vomiting that may confound safety or tolerability assessments.
  • 23. Hemodynamic instability, including clinically significant hypotension, hypertension, syncope, tachycardia or symptomatic orthostatic hypotension.
  • 24. Patients with evidence of serious risk of suicide at screening based on the C-SSRS

    1. Answers "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before Screening or,
    2. Answers "Yes" to any of the 5 items (C-SSRS - behavior) with an episode occurring within the 12 months before Screening, except for the participant having responded "Yes" to engaging in non-suicidal injurious behavior
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Participants will receive Dronabinol oral solution

    Dronabinol oral solution (target n=70)

    Drug: Dronabinol Oral Solution

  • Placebo comparator
    Participants will receive Placebo

    Control arm: Matching placebo (target n=70)

    Other: Placebo Control

Interventions

  • Dronabinol Oral Solution for Agitation in Patients with Alzheimer's Disease

  • OtherPlacebo Control

    Placebo (no THC)

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of dronabinol oral solution compared to placebo in reducing agitation in patients with AD.

    Agitation response is no greater than a partial response (i.e., Cohen-Mansfield Agitation Inventory \[CMAI\] 4-7 points improvement;

    Time frame: 12 weeks

  2. Change from baseline to Week 12 in the CMAI total score, comparing Dronabinol oral solution versus placebo

    Neuropsychiatric Inventory-Clinician \[NPI-C\] Agitation/Aggression domain 3-5 points improvement).

    Time frame: 12 weeks

07

Study locations

1 site
  • Finders Medical Center
    Bedford Park, SA Adelaide 5042, Australia
    • Aimee Cayzer · Contactrapmtu@sa.gov.au · 0482 130 622
    • Lauren Priest, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Until sponsor files a NDA, Sponsor will not be able to provide data because of dependence on results being confidential until filing of NDA.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 20, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 30, 2028
CompletionEst.
Aug 1, 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422311
Lead sponsor
Benuvia Therapeutics Inc.
Collaborators
Mandara
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 30, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Aimee Cayzer
Contact
rapmtu@sa.gov.au
0482 130 622
Lauren Priest, MD
principal investigator · Division of Rehabilitation, Aged Care and Palliative Care Flinders Medical Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion